Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis
- 20 January 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (2)
- https://doi.org/10.1128/aac.00927-20
Abstract
Antibiotic therapy is expected to impact host microbial communities considerably, yet many studies focused on microbiome and health are often confounded by limited information about antibiotic exposure. Given that antibiotics have diverse pharmacokinetic and antimicrobial properties, investigating the type and concentration of these agents in specific host specimens would provide much needed insight into their impact on the microbes therein. Here, we developed liquid chromatography mass spectrometry (LC-MS) methods to detect 18 antibiotic agents in sputum from persons with cystic fibrosis. Antibiotic spike-in control samples were used to compare three liquid extraction methods on the Waters Acquity Quattro Premier XE. Extraction with dithiothreitol captured the most antibiotics and was used to detect antibiotics in sputum samples from 11 people with cystic fibrosis, with results being compared to the individuals' self-reported antibiotic use. For the sputum samples, two LC-MS assays were used; the Quattro Premier detected nanomolar or micromolar concentrations of 16 antibiotics, whereas the Xevo TQ-XS detected all 18 antibiotics, most at sub-nanomolar levels. In 45% of tested sputum samples (71/158), at least one antibiotic that was not reported by the subject was detected by both LC-MS methods, a discordance largely explained by the thrice weekly administration and long half-life of azithromycin. For ∼37% of samples, antibiotics reported as taken by the individual were not detected by either instrument. Our results provide an approach for detecting a variety of antibiotics at the site of infection, thereby providing a means to include antibiotic usage data into microbiome studies.Funding Information
- HHS | NIH | National Heart, Lung, and Blood Institute (5R01HL136647-04)
This publication has 75 references indexed in Scilit:
- Metagenomics and metatranscriptomics: Windows on CF-associated viral and microbial communitiesJournal of Cystic Fibrosis, 2013
- The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of ExacerbationsPLOS ONE, 2012
- Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiotaProceedings of the National Academy of Sciences of the United States of America, 2012
- Decade-long bacterial community dynamics in cystic fibrosis airwaysProceedings of the National Academy of Sciences of the United States of America, 2012
- Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis SubjectsAntimicrobial Agents and Chemotherapy, 2011
- Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 2007
- Levofloxacin Pharmacokinetics in Adult Cystic FibrosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007
- Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trialThorax, 2006
- Linezolid Pharmacokinetics in Adult Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2004
- Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosisThe Journal of Pediatrics, 1984